Search Within

Lymphoma

Formats
  1. Meeting Abstract (1383)
  2. Journal Article (1063)
  3. Review (65)
  4. Book Section (64)
  5. Editorial (38)
  6. Research Letter (38)
  7. Guidelines (19)
  8. Conference Paper (15)
  9. Correspondence (13)
  10. Miscellaneous (6)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2708)
  2. Department of Medicine (2708)
  3. Hematologic Malignancies, Division of (2708)
  4. Population Sciences Research Program (748)
  5. Survivorship Research (657)
  6. Hematology-Oncology Fellows (544)

More Groups

People
  1. Andrew Zelenetz (784)
  2. Steven Horwitz (669)
  3. Maria Palomba (446)
  4. Ariela Noy (373)
  5. David Straus (361)
  6. Alison Moskowitz (360)

More People

Years
  1. 2025 (52)
  2. 2024 (144)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (876)
  2. Journal of Clinical Oncology (277)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (84)
  5. British Journal of Haematology (81)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (941)
  2. American Society of Clinical Oncology (293)
  3. Elsevier Inc. (189)
  4. Wiley Blackwell (174)
  5. John Wiley & Sons (97)
  6. Nature Publishing Group (94)

More Publishers

Results (2708)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Results from the first phase 1 clinical study of DR-01, a non-fucosylated anti-CD94 targeting antibody in patients with relapsed/refractory cytotoxic lymphomas: Dose escalation and optimization
    Meeting Abstract

    Zain, J.; Iyer, S. P.; Marchi, E.; Gandhi, M.; Kim, Y. H.; Khodadoust, M. S.; Brammer, J. E.; Poh, C.; Porcu, P.; Dilley, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CAR-tography: Longitudinal mapping of CAR-T toxicities across B-cell malignancies reveals biologically distinct and prognostically relevant toxicity phenotypes
    Meeting Abstract

    Rejeski, K.; Fei, T.; Luna, A.; Alhomoud, M.; Valtis, Y. K.; Nishimura, N.; Gomez-Llobell, M.; Accav, N. G.; Beyar-Katz, O.; Raj, S. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Burden of idiopathic multicentric Castleman disease (iMCD) in the US: A population-level real world analysis using a health-claims dataset
    Meeting Abstract

    Noy, A.; Ohgami, R.; Munshi, N. C.; Siddiqi, I.; Dacus, K. C.; Saltis, A. W.; Shupo, F.; Princic, N.; Evans, K.; Mukherjee, S.
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab with dose-adjusted EPOCH is feasible in newly diagnosed plasmablastic lymphoma: AIDS Malignancy Consortium 105
    Meeting Abstract

    Noy, A.; Barta, S. K.; Kwon, D.; Baiocchi, R.; Ramos, J. C.; Rubinstein, P.; Chadburn, A.; Ambinder, R. F.
    Blood (2024)

    Fulltext@MSK | Save
  • Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center
    Meeting Abstract

    Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final analysis of the safety and efficacy of venetoclax in combination with Pola-R-CHP for untreated high-risk BCL-2-positive B-cell lymphoma including double/triple hit lymphoma
    Meeting Abstract

    Diefenbach, C. S.; Zelenetz, A. D.; Herbaux, C.; Tani, M.; Houot, R.; Bastos-Oreiro, M.; Tilly, H.; Gastinne, T.; Thieblemont, C.; Leung, W.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improving outcomes in plasmablastic lymphoma: A multicenter experience from an American cohort
    Meeting Abstract

    Hamby, M.; Egleston, B.; Frosch, Z. A. K.; Steiner, R. E.; Noy, A.; Carvajal, V.; Tolu, S. S.; Jean-Louis, G.; Amengual, J. E.; Patel, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save